dc.contributor.author | Orkin, C | |
dc.contributor.author | Ring, K | |
dc.contributor.author | Smuk, M | |
dc.date.accessioned | 2024-06-12T07:41:10Z | |
dc.date.available | 2024-05-17 | |
dc.date.available | 2024-06-12T07:41:10Z | |
dc.date.issued | 2024-06-10 | |
dc.identifier.citation | Ring K, Smuk M, Shongwe M, et al. Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net). HIV Med. 2024; 1-10. doi:10.1111/hiv.13679 | en_US |
dc.identifier.issn | 1468-1293 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/97399 | |
dc.description.abstract | Introduction
Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods
Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results
In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7–11.3). In total, 97% of injections were administered within the ±7-day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion
In this large UK-based cohort, robust approval processes and clinic protocols facilitated on-time injections and low rates of both discontinuation and virological failure. | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | HIV Medicine | |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in anymedium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | |
dc.title | Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net) | en_US |
dc.type | Article | en_US |
dc.rights.holder | © 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. | |
pubs.notes | Not known | en_US |
pubs.publication-status | Accepted | en_US |
dcterms.dateAccepted | 2024-05-17 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |